Albertsons Companies, Inc.

Albertsons Companies, Inc. (ACI) Market Cap

Albertsons Companies, Inc. has a market capitalization of $7.98B.

Price: $16.14

-0.22 (-1.34%)

Market Cap: 7.98B

NYSE · time unavailable

CEO: Susan D. Morris

Sector: Consumer Defensive

Industry: Grocery Stores

IPO Date: 2020-06-26

Website: https://www.albertsonscompanies.com

Albertsons Companies, Inc. (ACI) - Company Information

Market Cap: 7.98B|Sector: Consumer Defensive

Company Profile

Albertsons Companies, Inc., through its subsidiaries, engages in the operation of food and drug stores in the United States. The company's food and drug retail stores offer grocery products, general merchandise, health and beauty care products, pharmacy, fuel, and other items and services. It also manufactures and processes food products for sale in stores. As of February 26, 2022, it operated 2,276 stores under various banners, including Albertsons, Safeway, Vons, Pavilions, Randalls, Tom Thumb, Carrs, Jewel-Osco, Acme, Shaw's, Star Market, United Supermarkets, Market Street, Haggen, Kings Food Markets, and Balducci's Food Lovers Market; and 1,722 pharmacies, 1,317 in-store branded coffee shops, 402 adjacent fuel centers, 22 distribution centers, and 20 manufacturing facilities, as well as various digital platforms. The company was founded in 1860 and is headquartered in Boise, Idaho.

Analyst Sentiment

67%
Buy

From 19 Active Polls

1Y Forecast: $19.56

▲ +21.2% Potential Upside

Consensus Target Metrics

Low Bound

$14

Median

$20

High Bound

$23

Average

$20

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$19.56
▲ +21.19% Upside
Low Target
$14.00
-13% Risk
Median Target
$20.00
24% Mid
High Target
$23.00
43% Max
Consensus
Buy
12 / 23 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MFeb 28, 2026Nov 29, 2025Sep 6, 2025Jun 14, 2025Feb 22, 2025Nov 30, 2024Sep 7, 2024Jun 15, 2024
Market Cap ($M)7,9829,1249,75010,81312,15911,91111,48510,68711,578
Enterprise Value ($M)23,08024,22224,98125,83526,31825,79625,48924,60525,425
Price to Earnings Ratio (P/E)37.84-4.748.3116.0412.8617.337.1718.3612.03
Price/Earnings-to-Growth Ratio (PEG)-0.807.560.40130.165.960.37
Price to Sales Ratio (P/S)0.100.450.510.570.490.630.610.580.48
Price to Book Ratio (P/B)4.484.973.903.513.773.523.413.543.97
Price to Free Cash Flow Ratio (P/FCF)3.8131.418.2124.1871.6143.47214.282740.1927.70
Enterprise Value to Sales (EV/Sales)1.201.311.371.061.371.361.331.05
Enterprise Value to EBITDA (EV/EBITDA)6.74141.4822.9228.0321.2228.8623.0728.3220.92
Debt to Equity Ratio4.418.336.174.974.444.194.224.704.85

ACI Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$16.14
Intrinsic Value$41.73
Market Alignment
Undervalued by 158.6%relative to calculated intrinsic value
9.00%
Exp: 1%1%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$2.70B
Perpetuity TV Value$50.76B
Discounted TV (PV)$21.44B
TV Weighting %58.1%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ALBERTSONS COMPANY INC CLASS A (ACI) — Investment Overview

🧩 Business Model Overview

Albertsons is a large-format grocery and pharmacy retailer that converts consumer demand into retail margin through a centralized distribution footprint and store-level execution. The value chain runs from upstream sourcing (manufacturers and wholesalers) to Albertsons’ logistics and merchandising, then to point-of-sale at owned/leased stores and pharmacy counters. Monetisation is primarily driven by (1) product gross margin (including mix effects such as higher-share private label and pharmacy), (2) operating leverage from running a dense store network, and (3) capturing value from loyalty and promotional mechanics that reinforce shopping frequency and basket size.

💰 Revenue Streams & Monetisation Model

Revenue is predominantly transactional and comes from grocery baskets, pharmacy services, and fuel/other ancillary offerings. The margin architecture is best understood as a blend of:

  • Grocery gross margin: supported by purchasing scale, category management, and assortment discipline; challenged by commodity and freight cycles.
  • Private label monetisation: typically improves margin resilience versus branded-only competitors, assuming stable consumer acceptance and disciplined quality/cost controls.
  • Pharmacy contribution: adds both margin and traffic-generation; it also provides a more recurring element through prescription volumes versus core grocery.
  • Operating cost absorption: distribution density, store productivity, and labor/technology efficiency determine whether gross profit translates into earnings.

Overall profitability is most sensitive to (1) product mix and promotional intensity, (2) shrink and shrink-related controls, and (3) labor and occupancy costs relative to sales throughput.

🧠 Competitive Advantages & Market Positioning

Albertsons’ competitive positioning is grounded in scale/distribution leverage and private label resistance. These factors can help defend share and margin in a mature, price-competitive retail market, even though consumer switching costs are low.

  • Scale & distribution leverage: Albertsons benefits from purchasing power and logistics optimization that can lower delivered cost per unit and improve inventory availability—critical in grocery where out-of-stocks and waste directly impair profitability.
  • Private label economics: maintaining cost-advantaged private label programs can reduce dependence on branded pricing power. Competitors face friction in matching both cost and quality at scale.
  • Store network density & service mix: the ability to pair grocery with pharmacy service lines supports traffic durability and improves sales productivity per store footprint.

Competitive benchmarking (industry peers):

  • Kroger Co. (KR): also emphasizes scale and private label, running a similar grocery + pharmacy model. Albertsons competes on regional store footprint, merchandising execution, and distribution cost discipline.
  • Walmart (WMT): competes through massive general merchandise scale and everyday-low-price pricing power. The differentiation tends to be category assortment depth, grocery freshness execution, and pharmacy/service adjacency rather than pure pricing volume.
  • Target (TGT): overlaps in discretionary and certain grocery-adjacent categories but is structurally different in store format and assortment strategy. Albertsons’ advantage centers on being a dedicated grocery/pharmacy operator with higher grocery share of wallet.

Compared with these rivals, Albertsons’ industry focus remains squarely on food-at-home and pharmacy-enabled grocery, where distribution execution and private label economics can be more decisive than brand-led differentiation.

🚀 Multi-Year Growth Drivers

Growth in grocery retail is typically achieved through a mix of modest traffic expansion, share shifts among value-conscious consumers, and margin management. Over a 5–10 year horizon, the most durable drivers include:

  • Share capture via value positioning: private label expansion and tighter merchandising can support share resilience when consumer budgets tighten.
  • Operating efficiency & productivity: technology-enabled inventory accuracy, labor scheduling, and better promotional calibration can improve earnings quality without relying on top-line growth alone.
  • Pharmacy and adjacent services: prescriptions and pharmacy-driven basket effects can support steadier contribution margins than pure grocery.
  • Omnichannel execution: pickup/delivery capabilities can increase customer convenience and basket size, provided fulfillment costs are tightly controlled.
  • Category mix optimization: higher-margin categories (where demand supports it) and improved shrink controls can expand gross profit dollars through cycle.

While the grocery TAM is mature, the practical addressable opportunity is less about market size and more about capturing share and reducing cost-to-serve through scale execution.

⚠ Risk Factors to Monitor

  • Margin pressure from competitive pricing: aggressive promotional cycles can compress gross margin and offset private label benefits.
  • Input cost and logistics volatility: commodities, freight, and labor inflation can create earnings drawdowns if price/mix cannot adjust fast enough.
  • Regulatory and antitrust scrutiny: store network changes, pharmacy regulations, and consolidation-related constraints can affect strategic flexibility.
  • Labor and occupancy dynamics: wage rates, scheduling complexity, and lease terms influence store-level operating leverage.
  • Execution risk in omnichannel: delivery/pickup expansion can raise fulfillment costs and working-capital needs if scale economics do not materialize.
  • Supply chain and shrink: inventory accuracy, theft prevention, and food waste discipline are structural to grocery economics.

📊 Valuation & Market View

Equity valuation for grocery retailers often reflects the market’s assessment of (1) sustainable operating margin, (2) free cash flow conversion, and (3) balance-sheet risk. Market participants commonly frame value using EV/EBITDA and earnings/FCF multiples, with key qualitative adjustments for:

  • Same-store sales quality (mix and promotional intensity versus purely unit volume)
  • Gross margin stability driven by private label penetration and procurement discipline
  • Operating expense leverage from distribution productivity and store labor efficiency
  • Working-capital efficiency (inventory turns and cash conversion)
  • Capital intensity associated with store refresh, technology, and logistics capabilities

🔍 Investment Takeaway

Albertsons’ long-term thesis centers on defending profitability in a structurally competitive market through scale/distribution leverage and private label monetisation, supported by a grocery-plus-pharmacy model that can stabilize traffic and contribution margins. The investment case is strongest when operational execution sustains gross profit dollars and cost-to-serve improvement offsets pricing and cost volatility.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for ACI.

businesswire.com2026-06-08

ACI Sky™ Workbench Verified by Fannie Mae and Freddie Mac to Support UAD 3.6 Specifications

SANTA ANA, Calif.--(BUSINESS WIRE)--First American Mortgage Solutions, LLC, a part of the First American (NYSE: FAF) family of companies, today announced that its ACI Sky™ Workbench platform has been verified by Fannie Mae and Freddie Mac to support the Uniform Appraisal Dataset (UAD) 3.6 specifications. UAD 3.6 appraisal reports will be required by the government-sponsored enterprises (GSEs) for new appraisal reports submitted to the Uniform Collateral Data Portal® (UCDP®) on and after Nov. 2,.

zacks.com2026-05-26

Is the Options Market Predicting a Spike in Albertsons Stock?

Investors need to pay close attention to ACI stock based on the movements in the options market lately.

zacks.com2026-05-25

Here's Why Albertsons Companies, Inc. (ACI) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

fastcompany.com2026-05-25

Albertsons is closing stores: See a list of doomed locations for 2026 as the grocery giant evaluates its footprint

Shoppers in local communities across several states may discover that they have fewer supermarkets to choose from this year.

businesswire.com2026-05-14

ACI Worldwide and Security Bank Philippines Set New Benchmark for Enterprise-wide Payments Modernization

OMAHA, Neb. & SINGAPORE--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, and Security Bank Corporation (Security Bank), a leading universal bank in the Philippines, today announced that they won the "Best Payment Technology Initiative in Asia Pacific" at The Asian Banker (TAB) Global Financial Technology Innovation Awards 2026. This award recognizes Security Bank and ACI Worldwide's transformation of payment infrastructure by consolidating fra.

pymnts.com2026-05-14

Albertsons Builds AI That Grades Produce Before It Ships

Albertsons wants to know whether a grape is bad before it ever reaches a store shelf.

nypost.com2026-05-13

Doomsday warning for Albertsons as shoppers make major change, flagging finances revealed

Albertsons shoppers are turning away from one of the supermarket giant's most profitable aisles.

businesswire.com2026-05-13

Albertsons Companies Announces AI-Powered Supply Chain Tool to Further Enhance Produce Quality Control and Consistency

BOISE, Idaho--(BUSINESS WIRE)--Albertsons Cos. Announces AI-Powered Supply Chain Tool to Further Enhance Produce Quality Control & Consistency; Uses Google Cloud's Gemini Enterprise.

businesswire.com2026-05-12

ACI Worldwide to Attend Upcoming Investor Conferences

OMAHA, Neb.--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, today announced that company management will participate in the following investor conferences: J.P. Morgan 2026 Global Technology, Media and Communications Conference, May 18 in Boston (President and CEO Thomas Warsop, CFO Bobby Leibrock, and SVP John Kraft) Baird 2026 Global Consumer, Technology & Services Conference, June 4 in New York City (CFO Bobby Leibrock and SVP John Kra.

zacks.com2026-05-08

Here's Why Albertsons Companies, Inc. (ACI) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

businesswire.com2026-05-07

ACI Worldwide Reports Strong First Quarter 2026 Results and Raises Full-Year Guidance

OMAHA, Neb.--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), a leading provider of global payments technology, today announced financial results for the quarter ended March 31, 2026. “Payments modernization continues to accelerate, and ACI is at the center of it,” said Thomas Warsop, President and CEO of ACI Worldwide. “In the quarter, Real Time Payments and Merchant each grew more than 20%, Biller delivered 10% growth on top of last year's double‑digit performance, and new ARR bookings grew 39%.

businesswire.com2026-05-05

Peru, Chile and Argentina Enter a New Phase of Growth Driven by Real-Time Payments, ACI Worldwide Report Finds

OMAHA, Neb.--(BUSINESS WIRE)--Peru, Chile and Argentina are entering a decisive stage of their real‑time payments modernization journeys, with adoption expected to drive economic growth and financial inclusion across the region, according to the Real-Time Payments: Economic Impact and Financial Inclusion report. The study was commissioned by ACI Worldwide, and conducted by the Cebr (Centre for Economics and Business Research), a leading economic think tank.* By 2028, real-time payments are fore.

zacks.com2026-04-30

Albertsons Bets on Curbside Pharmacy to Drive Customer Growth

ACI expands DriveUp & Go pharmacy pickup to 1,700 locations, letting customers collect prescriptions curbside without leaving their cars.

globenewswire.com2026-04-30

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 2026 Initiated final cohort, AD4, in ABATE Phase 1b/2 trial of ACI-24 to treat Alzheimer's Disease triggers milestone payment, as announced separately today Amended Morphomer® Tau collaboration with Lilly reflects growing excitement for targeting intracellular Tau and significant progress with our Morphomer® small molecules Approaching multiple milestones including 12-month interim results of the AD3 cohort in ABATE in Q2 2026 and full data from Part 1 of ACI-7104 VacSYn Phase 2 trial expected in H2 2026 Cash resources of CHF 74.8 million as of March 31, 2026, provide funding into Q4 2027 Lausanne, Switzerland, April 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today provided financial and corporate updates for the quarter ended March 31, 2026. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The progress in our collaborations with Takeda and Eli Lilly reflect great confidence in our anti-Abeta active immunotherapy and Tau aggregation inhibitor small molecules, respectively.

businesswire.com2026-04-28

Albertsons® Companies Expands Free Curbside Prescription Pickup Nationwide, Giving Customers More Flexibility and Convenience

BOISE, Idaho--(BUSINESS WIRE)--Albertsons Companies announced the nationwide expansion of DriveUp & Go to include free curbside pickup for eligible pharmacy prescriptions.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-02-28

"ACI’s latest quarter (ending 2026-02-28) showed Revenue of $20.25B and Net Income of -$0.48B (EPS -0.94). QoQ, Revenue fell from $24.88B (2025-06-14) to $20.25B, with a similar contraction from $24.88B in 2025-06-14 through the subsequent quarters. YoY, Revenue was down versus $18.92B one year ago (2025-09-06), implying modest growth of ~+7.0% on the most comparable YoY pairing available in the provided set, but the path is volatile rather than steadily improving. Net Income deteriorated sharply YoY at the quarterly level: from +$0.17B (2025-09-06) to -$0.48B (2026-02-28), a decline of ~-377%. Profitability is compressing. The most recent quarter swung to a loss, and management’s earnings power appears unstable across the last four quarters (positive net income in two prior quarters). Cash flow quality remains supportive but not robustly improving: Free Cash Flow (FCF) of $0.29B (latest) is down from $1.19B (2025-11-29) and $0.45B (2025-09-06), though still positive. Dividends continue (~$0.17/share latest), with payout broadly constrained; the latest payout ratio is negative due to losses. Balance sheet resilience is mixed: total equity fell from $3.22B (2025-06-14) to $1.84B (2026-02-28), while total assets were relatively stable around ~$26–27B, implying higher leverage. Total shareholder return is pressured: the stock is down -21.0% over 1 year, which hurts momentum and valuation support. With consensus valuation targets (~$20.38) below the current price context ($16.7), sentiment is cautious but not panicked."

Revenue Growth

Fair

Latest Revenue was $20.25B (2026-02-28). QoQ trend is volatile with contraction from $24.81B (2025-06-14) to $20.25B. YoY based on available comparable quarter, Revenue increased ~+7.0% vs $18.92B (2025-09-06), but not on a consistent run-rate.

Profitability

Neutral

Net Income swung from profits to a loss: +$168.5M (2025-09-06) to -$480.8M (2026-02-28), ~-377% YoY at the quarterly level. EPS fell to -0.94 from +0.30 previously; margins appear to be contracting with the loss quarter.

Cash Flow Quality

Neutral

FCF remains positive but is weakening: $290.5M (latest) vs $1.187B (2025-11-29) and $447.1M (2025-09-06). Dividends are ongoing (~$76–86M per quarter previously); latest payout ratio is distorted by losses, but cash coverage still looks imperfectly resilient rather than deteriorating into negative FCF.

Leverage & Balance Sheet

Caution

Total assets were broadly stable (~$26–27B), but equity declined materially from $3.22B (2025-06-14) to $1.84B (2026-02-28). Net debt remains elevated (~$14.2B to ~$15.1B), reducing resilience if profitability stays weak.

Shareholder Returns

Neutral

Total return is likely negative given price momentum: stock is down -21.0% over 1 year. Dividend yield is low (~0.83%), so yield does not offset capital depreciation. No buyback data was provided.

Analyst Sentiment & Valuation

Neutral

Consensus target (~$20.38) sits above the current price context ($16.7), suggesting modest upside with a valuation floor implied by the high/low range ($29/$14). However, near-term fundamentals (earnings volatility) temper enthusiasm.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

ACI delivered resilient profitability in Q4 despite sharper-than-expected pharmacy-driven top-line pressure. Identical sales rose 0.7% but included ~145 bps net pharmacy headwinds versus the prior Q3 outlook (IRA pricing/mix ~105 bps and a further ~40 bps from GLP-1 growth moderation). Margin was partially protected because generics are structurally accretive, though gross margin still fell 25 bps YoY (27.2% excluding fuel/LIFO) largely from digital mix and reduced sales volume effects. Management emphasized operating leverage from a scaled productivity engine: FY25 showcased funding capacity for investment while generating adjusted EBITDA of $903M (including 53rd week). For 2026, guidance calls for adjusted EBITDA $3.85B–$3.925B and adjusted EPS $2.22–$2.32, alongside ~$600M share repurchases and capex $2.0B–$2.2B. The key near-term risk is ongoing IRA headwinds (~150 bps to reported identical sales) plus Q1 egg deflation effects; however, management expects sequential improvement into the back half supported by AI-enabled merchandising/labor/supply chain tools and loyalty/digital scale (including 90% lift in retail media pilot performance).

AI IconGrowth Catalysts

  • Digital penetration surpassed 10% in Q4; first-party digital contributed nearly 90% of 16% digital growth
  • AI-enabled shopping assistance driving meaningful lift in basket size and personalization (conversion/basket/loyalty)
  • Retail media: personalized ad pilots delivered 90% lift in conversion and click-through rates
  • Pharmacy customer lifetime value improvement from grocery+pharmacy engagement (pharmacy profitability improvement despite top-line pressure)
  • Food now / meal solutions: deli & prepared foods drive >1/3 of total trips; outsized share of wallet continuing to grow
  • Loyalty flywheel: membership grew 12% to >51 million; more redemption via cash-off option

Business Development

  • Retail media merchant partnerships (embedded into customer journey; “merchant partnerships” referenced; no named external partners/counterparties in transcript)
  • Opioid legal settlement framework: $774 million proposed nationwide opioid settlement payable over 9 years (legal framework, not a commercial partnership)
  • Gateway proprietary AI-powered tool for inventory efficiency and replenishment for promotional center store SKUs (internal product/tool)

AI IconFinancial Highlights

  • Identical sales +0.7% in Q4; net of ~145 bps pharmacy-related headwinds vs prior Q3 outlook of ~65–70 bps
  • Pharmacy headwind composition: ~105 bps from IRA pricing/mix pressure and generic-to-brand mix shift; additional ~40 bps from moderation in GLP-1 growth (tighter payer criteria + increased direct-to-consumer penetration)
  • ID sales margin impact favorable (generics structurally more accretive) offsetting top-line pressure
  • Gross margin: 27.2% in Q4, down 25 bps YoY excluding fuel and LIFO; mix shift from outsized growth in digital sales partially offset by productivity and surgical price investments
  • SG&A expense (ex fuel + opioid settlement framework): improved 2 bps YoY; SG&A rate unfavorable due to lower sales from pharmacy IRA impact
  • Adjusted EBITDA: $903 million in Q4 (including ~$68 million from the 53rd week); “better-than-expected adjusted EBITDA flow-through”
  • Adjusted EPS: $0.48 per diluted share in Q4
  • Full year 2025: identical sales +2%; adjusted EBITDA $3.9 billion
  • Effective tax rate guidance 2026: 24%–25%
  • Pharmacy IRA assumed as ~150 bps headwind to reported identical sales guidance for 2026

AI IconCapital Funding

  • Returned >$1.8 billion to shareholders in FY25: $322 million dividends and nearly $1.5 billion share repurchases
  • Completed $750 million accelerated share repurchase program (ASR) in FY25
  • Quarterly dividend increased 13% to $0.68 per share (announced during call)
  • Refreshed/renewed share repurchase authorization to $2.0 billion total after ASR completion; expected completion over ~3 years
  • 2026 share repurchases expected: ~$600 million during fiscal 2026
  • Net debt / adjusted EBITDA: 2.24x at year-end (capacity to fund growth/returns)
  • Opportunistic debt refinancing in Q4: refinanced $2.1 billion in 2 tranches (5.625% notes due 2032: $1.2B; 5.75% tack-on notes due 2034: $0.9B) using proceeds to refinance $1.35B 2027 and $0.75B 2028 maturities
  • FY25 capital expenditures: $1.84 billion

AI IconStrategy & Ops

  • 4 “big bets”: digital customer experience, merchandising intelligence, labor optimization, supply chain optimization (long-term structural initiatives)
  • Automation/AI across merchandising stores and supply chain to improve efficiency; productivity funded rather than short-term trade-offs
  • Supply chain: AI demand forecasting + computer vision for availability/quality/freshness; launched “Gateway” AI tool for promotional center store SKUs
  • Labor optimization: generative AI scheduling tools to improve forecast accuracy and labor efficiency
  • Merchandising intelligence: automated insights + intelligent pricing tools to improve category decision-making and structurally stronger margins; tools to reimagine price/promotional strategy and assortment decisions
  • Productivity scaling: $2.0 billion 3-year productivity program (reset from prior $1.5B expectation; ratable over 3 years)
  • Q4 capex/store footprint: remodeled 94 stores and opened 9 stores in FY25
  • Store optimization framework for 2026+: banner optimization, store modernization, market densification, and store rationalization where economics are structurally challenged

AI IconMarket Outlook

  • 2026 identical sales guidance: range 0% to 1% OR 1.5% to 2.5% excluding the 150 bps IRA headwind and assuming near-flat reported pharmacy sales
  • Q1 2026 identical sales: expected to track below full-year range (including IRA and significant ongoing egg deflation); management expects sequential improvement after Q1 and “likely positive in the back half”
  • Adjusted EBITDA 2026 guidance: $3.85B to $3.925B (top end ~2.5% growth excluding 53rd week impact in 2025)
  • Adjusted EPS 2026 guidance: $2.22 to $2.32, including approx. $600M of share repurchases
  • Capital expenditures 2026 guidance: $2.0B to $2.2B
  • Food inflation expectation: ~2% range (industry), though management noted they have not been passing through at the full 2% rate

AI IconRisks & Headwinds

  • Pharmacy headwinds from Inflation Reduction Act: ~145 bps net headwind to Q4 ID sales expectations; ~105 bps from IRA pricing/mix pressure and generic-to-brand mix shift; ~40 bps from GLP-1 growth moderation (tighter payer criteria; increased direct-to-consumer penetration)
  • Reported identical sales pressured by grocery affordability/units weakness in lowest income cohorts
  • Deflation and cycling prior-year egg shortages: expected to persist into Q1 2026
  • Gross margin headwind: mix shift impact from outsized growth in digital sales (digital margins still below grocery) and down 25 bps YoY excluding fuel and LIFO in Q4
  • Lower sales impacts: SG&A rate unfavorable due to lower sales from pharmacy IRA
  • Potential incremental pressure if higher fuel costs persist (fuel/transportation/distribution costs included in outlook; incremental risk if not temporary)

Sentiment: MIXED

Note: This summary was synthesized by AI from the ACI Q4 2025 (conference date: 2026-04-14) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for ACI.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (ACI)

© 2026 Stock Market Info — Albertsons Companies, Inc. (ACI) Financial Profile